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Running headline: MRI neurovascular changes in IPD and its phenotypes 
Abstract 
Neurovascular changes are likely to interact importantly with the neurodegenerative 
process in idiopathic Parkinson’s disease (IPD). Markers of neurovascular status (NVS) 
include white matter lesion (WML) burden and arterial spin labelling (ASL) measurements of 
cerebral blood flow (CBF) and arterial arrival time (AAT). We investigated NVS in IPD, 
including an analysis of IPD clinical phenotypes, by comparison with two control groups, one 
with a history of clinical cerebrovascular disease (CVD) (control positive, CP) and one 
without CVD (control negative, CN).  
Fifty-one patients with IPD (mean age 69.0 ± 7.7 years) (21 tremor dominant [TD], 24 
postural instability and gait disorder [PIGD] and 6 intermediates), 18 CP (mean age 70.1 ± 
8.0 years), and 34 CN subjects (mean age 67.4 ± 7.6 years) completed a 3T MRI scan 
protocol including T2-weighted fluid-attenuated inversion recovery (FLAIR) and ASL. 
IPD patients showed diffuse regions of significantly prolonged AAT, small regions of lower 
CBF and greater WML burden by comparison with CN subjects. TD patients showed lower 
WML volume by comparison with PIGD patients. These imaging data thus show altered NVS 
in IPD, with some evidence for IPD phenotype specific differences. 
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Idiopathic Parkinson’s disease (IPD) is the second most common neurodegenerative 
disorder, for which there are no effective disease modifying or neuroprotective agents. 
What drives the selective and progressive neuronal dysfunction and loss, the hallmark of 
neurodegeneration, remains elusive. Neurodegeneration is understood to result from a 
number of insults or key factors that act and interact over time leading to selective neuronal 
loss.1,2 Any of these factors found to be potentially modifiable may point to therapeutic 
opportunities.  
The ‘vascular’ hypothesis has recently gained much momentum, proposing a key role for 
neurovascular changes in neuronal dysfunction and loss.3-7 A number of preclinical studies 
have identified vascular changes as contributors to the neurodegenerative process, but 
clinical studies in this area remain equivocal.8,9 The nature and relevance of vascular 
changes may also differ between IPD clinical phenotypes perhaps reflecting 
pathophysiological differences.10 Clinical studies often use markers of conventional 
cerebrovascular disease (CVD), whether clinical (stroke, TIA) or imaging (white matter lesion 
[WML]) which may be insensitive to more subtle neurovascular alterations. Herein we have 
used the term ‘neurovascular status’ (NVS) to encompass the various structural and 
physiological neurovascular markers. 
 
Magnetic resonance imaging (MRI) arterial spin labelling (ASL) is a non-invasive tool which 
allows quantitative measures of cerebral blood flow (CBF) and arterial arrival time (AAT), the 
time taken for blood to travel from the labelling slab to the tissue of interest11,12. There are 
numerous studies showing CBF changes in IPD using both ASL13,14 and other imaging 
techniques.15 How and why these occur in the setting of IPD is poorly understood, as is the 
temporal relationship of CBF changes with neuronal loss. Whether, for instance, atrophic 
regions merely exhibit secondary hypoperfusion remains debatable.15 Therefore 
measurements of atrophy in addition to CBF are important to determine whether CBF 
alterations are simply reflective of areas of atrophy or not. AAT is longest in distal branches, 
especially in border zone (or watershed) areas.16,17 Alterations in AAT are considered likely 
to reflect chronic arteriolar vasodilatation, collateral flow and/or increased tortuosity of 
vessels.18,19  
 
Neurovascular alterations have previously been reported in MRI studies of IPD, including our 
own finding of prolonged AAT.20 However, little is known about how such changes might 
vary between clinical IPD phenotypes. In addition, the extent to which such alterations in 
NVS might either reflect comorbid conventional CVD, or could contribute to, or be a 
secondary effect of, the neurodegenerative process, is largely unknown.  
 
In this study we sought to (1) confirm and extend our previous finding of AAT prolongation 
in IPD, (2) investigate other markers of NVS including WML burden and also measures of 
brain volume changes (to determine the extent and location of any atrophy) and (3) make 
comparison between phenotypes and with relevant control groups, including both subjects 
with and without clinical CVD.  
  
Materials and Methods 
 
Approvals, recruitment, eligibility and consent 
Relevant approvals were obtained including ethics (North West – Preston Research Ethics 
Committee), research governance and local university approvals. The study was conducted 
in accordance with the principles of Good Clinical Practice (GCP). Recruitment of IPD 
patients was from Lancashire Teaching Hospitals (LTH) and Salford Royal Foundation Trust 
(SRFT).  Eligibility criteria for IPD participants were a clinical diagnosis of IPD fulfilling UK 
Parkinson’s disease society (UKPDS) brain bank (BB) criteria 
(http://www.ncbi.nlm.nih.gov/projects) without known clinical CVD (no history of TIA or 
stroke) or dementia.21 Participants with CVD were recruited from patients at LTH with a 
clinical diagnosis of stroke or TIA within the previous 2 years (at least 3 months post onset) 
supported by relevant brain imaging (control positive, CP). Controls without a history of 
either IPD or clinical CVD were also recruited (control negative, CN). All groups were 
matched for age. All participants were required to provide written informed consent and 
had capacity to do so.  
 
Clinical assessments and phenotyping 
IPD phenotype was assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS) 
(http://www.mdvu.org/library/ratingscales/pd/updrs.pdf) during the scan visit.  Participants 
with IPD were classified into three subtypes (tremor dominant [TD], postural instability and 
gait disorder [PIGD], intermediate) by Jankovic's method.22 Disease severity was measured 
using the Hoehn and Yahr rating scale.23 No alterations were made to the participants’ 
medications for the study protocol. Routine clinical baseline data were also recorded and 
the levodopa equivalent doses (LEDD) calculated.24 A battery of clinical scales was also 
administered, including the Montreal Cognitive Assessment (MoCA) (www.MoCAtest.org), 
details of which are beyond the scope of this paper. Data from participants in an earlier 
study were included to provide sufficient numbers for phenotypic comparison, comprising 
14 patients with IPD and 14 controls scanned on a 3T Philips Achieva MRI system using an 8 
channel coil at Salford Royal Hospital.20 Demographics and clinical data were compared 




All participants underwent an approximately 1 hour long imaging protocol, on a 3T Philips 
Achieva MRI system. Twenty-eight participants (14 IPD and 14 CN) were scanned using an 8 
channel 8 head coil at Salford Royal Hospital and the remaining participants using a 32 
channel head coil at the Wellcome Trust Clinical Research Facility (WTCRF) in Manchester.   
Involuntary movements in participants were minimised using padding within the head coil. 
A T2-weighted FLAIR image was acquired with the following parameters: TR 11s, TI 2.8s, TE 
120 ms, in-plane resolution of 0.45mm, 30 axial slices of 4mm thickness with 1mm gap 
covering the whole brain. A Look-Locker (LL) ASL sequence was used,25 with STAR labelling26 
and 4 readout times of 800, 1400, 2000, 2600 ms, TR: 3500 ms; TE 22ms; flip angle 40 
degrees; 3.5 x3.5 x 6 mm voxels with 1mm gap between slices; 15 slices covering the 
cerebrum but not the cerebellum with bipolar ‘vascular crusher’ gradients (added to 
dephase fast flowing spins and so remove large vessel signal). Sixty pairs of label and control 
images were collected with acquisition time of 7 minutes. The labelling slab was 15 cm with 
a 10 mm gap between labelling and imaging regions. To allow quantification of CBF an 
additional scan was acquired with TR = 10s and 15 read-out times (from 800 to 9200 ms) in 
order to estimate the equilibrium magnetisation of the brain.  A 3D T1-weighted image with 
1mm isotropic resolution was also collected. 
 
Data analysis 
All the data analyses were performed to consider differences between the IPD group as a 
whole and the CN group (with no history of IPD or clinical CVD), between the IPD group as a 
whole and the CP group (no history of IPD, but with history of clinical CVD) and between the 
PIGD and TD groups. These comparisons were selected to establish whether IPD is 
associated with vascular changes different from those seen in CVD, and whether any such 
differences vary between clinical IPD phenotypes. In addition voxel-wise analyses included 
comparisons between PIGD and CN, and TD and CN, to further investigate regional 
differences between phenotypes. Voxel-wise analysis of data from the CP group was not 
considered due to the likely heterogeneous spatial pattern of neurovascular abnormalities.  
ASL data were analysed using in-house MATLAB (Mathworks, MA, USA) routines using a 
single blood compartment model, adapted for LL readout.20 CBF and AAT maps were 
calculated and CBF maps were corrected for atrophy using the same method as Johnson et 
al., according to the proportion of grey matter (GM) and white matter in each voxel 
obtained from the segmented T1-weighted image.
27 Whole brain values for CBF and AAT 
were calculated using a simple threshold mask based on the ASL control images on an 
individual basis.  
Voxel-wise analysis was also performed using the SPM8 PET toolbox 
(http://www.fil.ion.ucl.ac.uk/spm/) to determine any regionally specific differences 
between the groups. The groups were age, but not gender matched, therefore gender was 
included as a regressor. In addition all the data was reanalysed using a gender matched 
control group. An additional group comparison between the images from the PIGD and TD 
phenotypes was performed including nuisance co-variates of disease severity (UPDRS 111), 
disease duration and LEDD score to determine the effect of these variables on any 
phenotypic imaging differences.  Image pre-processing in SPM included (1) motion 
correction, (2) registration and normalisation of the control ASL image to the EPI template 
within SPM, and application of this procedure to the CBF and AAT images, and (3) spatial 
smoothing of the normalised images using an 8mm full-width-half-maximum kernel. Voxel-
wise comparisons of CBF and AAT between the groups were carried out using a two-sample 
unpaired t-test (unequal variances). Regions were considered significant at a p value < 0.001 
uncorrected, with a minimum cluster size of 50 voxels. Further analysis using Family-Wise 
Error (FWE) correction for multiple comparisons at the cluster level was performed.   The 
MNI coordinates were used to locate areas of difference using xjview V 8.14 
(http://www.alivelearn.net/xjview8/).  
Voxel-based morphometry (VBM) was performed on the T1-weighted images in SPM8 
following standard procedures (http://www.fil.ion.ucl.ac.uk/~john/misc/VBMclass10.pdf), 
including modulation to allow comparisons of volumes, proportional scaling to individual 
intracranial volume and smoothing using an 8mm FWHM kernel. 
WML burden was assessed semi-quantitatively using visual rating scales.28,29 WML volume 
was also calculated using the lesion segmentation toolbox (LST) in SPM8 with a threshold of 
0.3. This threshold was chosen as it gave the most accurate estimates in a sub-study 
comparing WML volume estimates from LST with those from semi-automated lesion-
growing methods on a subset of the data (n=51, including representation from all groups).30 
Differences between IPD and CN and CP groups for WML burden were measured using the 
Fazekas periventricular hyperintensity (PVH) and deep white matter hyperintensity (DWMH) 
and the Wahlund rating scales. Wahlund and Fazekas scores were stratified into 3 groups: 
mild (Wahlund score of 0-4; Fazekas 0-1); moderate (Wahlund: 5-10; Fazekas:2); and severe 
(Wahlund: >10; Fazekas: 3).31 Fazekas scores were combined into categories (0-1) and 2 
where appropriate since the majority of patients scored 1 or 2. The scales were tested using 
Pearson’s Chi squared in SPSS 22, WML volume was compared between the groups using 
the Mann-Whitney U test in SPSS 22; taking into account the non-parametric nature of the 
results. Differences were considered significant if p < 0.05. 
Finally, the association between imaging findings and MOCA score was assessed by 
Pearson’s correlation.    
Results 
Participants 
Fifty one IPD patients were recruited (21 TD, 24 PIGD and 6 intermediates), 18 CP subjects 
with CVD (14 with ischaemic stroke, 4 with single or multiple TIAs) (mean time, in years, 
since diagnosis 1.1±0.7) and 34 CN subjects (table 1). All groups were matched for age; a 
difference in gender between the CN group and the other groups was included as a 
regressor in the ASL analysis. IPD severity and LEDD score varied between the IPD 
phenotypes, as expected. A greater proportion of PIGD patients were medicated with L-
DOPA (92%) compared with TD patients (67%), but DA agonist medication was similar (50% 
PIGD and 48% TD).  MoCA score was significantly lower for the IPD group compared to the 
CN group (p<0.001) but was similar to the CP group. The PIGD group had significantly lower 
MoCA score than the TD group (p<0.001).   
CBF 
Whole brain CBF did not differ significantly between the IPD and CN groups, IPD and CP 
groups nor between the IPD phenotypes (Figure 1, Table 1). The voxel-wise analyses did 
reveal areas of lower CBF in the IPD group by comparison with the CN group, which were 
predominantly posterior with a few frontal regions (Figure 2, Table 2). There was only one 
area of higher CBF in the IPD group compared to the CN group, in the right lateral globus 
pallidus (MNI coordinates [20 -2 4], cluster size 85 voxels, peak t-value 3.7, peak p-value 
0.001).  The TD and PIGD groups, when compared to the CN group, revealed phenotype 
specific patterns of hypoperfusion, with only the PIGD group showing areas of 
hyperperfusion compared to the CN group (in the right lateral globus pallidus). A direct 
comparison of the PIGD and TD groups however did not reveal any significant difference in 
CBF, which remained the case when nuisance covariates of disease severity (UPDRS 111), 
disease duration and LEDD score were included in the analysis. In summary, we found 
modest reductions in CBF in IPD in comparison to CN, and little difference compared to CP. 
There were no significant phenotypic differences.  
AAT 
Whole brain AAT revealed significantly longer AAT in the IPD group as a whole compared to 
both the CN group (p < 0.005) and the  CP group (p < 0.05) (Figure 1, Table 1). No significant 
differences were observed between IPD phenotypes. 
Voxel-wise analyses revealed widespread regions of significantly increased AAT in the IPD 
group compared to the CN group (Figure 3, Table 3). There were no regions in the brain 
where AAT was significantly shorter in the IPD group compared to the CN group. The TD 
group revealed a more diffuse pattern of prolonged AAT than the PIGD group when 
compared to the CN group, with a few of these regions reaching significance when directly 
comparing the TD and PIGD groups. However, no differences between the TD and PIGD 
groups were observed on direct comparison when nuisance covariates of disease severity 
(UPDRS 111), disease duration and LEDD score were included in the analysis. 
Re-analysis of the data with the gender matched control group and re-analysis with the 
removal of the preliminary data (obtained from our earlier study) yielded similar results to 
those discussed in the above sections. 
VBM analysis 
The voxel-wise analysis did reveal areas of reduced GM volume in the IPD group as a whole 
compared to the CN group, predominantly in the temporal lobes (Figure 4). Comparison of 
TD to PIGD revealed one region of lower GM volume in the TD group in the frontal cortex, 
but this was no longer significant when nuisance covariates of disease severity (UPDRS 111), 
disease duration and LEDD score were included in the analysis.  
WML burden 
All the WML scores were significantly higher in the IPD group as a whole compared to the 
CN group, with no significant differences between the IPD and CP groups or between the 
IPD phenotypes. 
A trend towards greater WML volume was seen in the IPD group compared to the CN group 
(p=0.08). WML volume was significantly higher in the CP group when compared with the IPD 
group and significantly higher in the PIGD group by comparison with the TD group (Table 4).  
Correlations with cognitive impairment 
In order to further understand the phenotypic differences in cognitive impairment we 
assessed the correlation of individual imaging metrics against MoCA score within the IPD 
group. We considered WML volume, global AAT and regional CBF values from the regions of 
hyper-perfusion (globus pallidus) and hypo-perfusion (predominantly occipital cortex) as 
identified by the IPD vs CN voxel-wise analysis (Figure 1). Higher WML volume was 
associated with lower MoCA score (r=-0.39, p=0.005) across the IPD group and this 
association remained significant within the TD group (TD r=-0.45, p=0.03, PIGD r=-0.29, 
p=0.2). However there was no association between AAT and MoCA score (r=-0.16, p=0.3) or 




This study used a multi modal MRI approach in a clinical study to better understand NVS in 
IPD and revealed key differences in NVS namely AAT prolongation, reduced CBF and 
differences in WML burden in IPD patients by comparison with age matched controls with 
and without CVD. Within the IPD group phenotype specific differences were also revealed. 
This study confirmed our previous findings of diffuse prolonged AAT in IPD patients 
compared to controls; whole brain analysis revealed this prolongation to be greater in IPD 
patients than in controls both with and without CVD. As the IPD group had significantly 
fewer vascular risk factors than the CP group, this raises the interesting possibility that 
mechanisms of AAT prolongation might be independent of, or at the least driven by other 
factors than, conventional CVD. The prolonged AAT appeared more diffuse in the TD 
compared to PIGD group (Figure 3), and this may be related to the shorter disease duration 
and lower disease severity in TD compared to PIGD as voxel-wise differences were no longer 
seen on direct comparison when these factors were taken into account. Given that the TD 
phenotype is generally considered to have a more benign clinical course), it might be 
inferred that prolongation of AAT appears somewhat ‘protective’.  
Indeed AAT has been measured in acute stroke studies revealing areas of prolonged AAT 
generally reflecting preserved perfusion, lack of progression to infarct and more minor 
symptoms.32-34 Prolonged AAT has been postulated to be reflective of recruitment of 
collaterals33,35 or secondary to altered vasculature causing a decrease in the flow velocity, 
for example, increased tortuosity, altered vascular wall diameter/compliance and chronic 
vasodilation.36-39  
WML burden, as measured by visual rating scales, was higher in the IPD patients than in the 
CN subjects – in keeping with our earlier work.9 WML rating scales also revealed a greater 
burden in CP than IPD which is to be expected yet also suggests conventional CVD may not 
be driving AAT prolongation. Of note WML volume (arguably a more accurate measure of 
WML burden as rating scales do not take into account the size/volume of the lesions) was 
significantly higher in the PIGD than in the TD group, indeed PIGD WML volumes were 
comparable control subjects with CVD. This strengthens the case for a differential pattern of 
changes in NVS between IPD phenotypes. WML volume showed a significant association 
with MoCA score showing the influence of WML volume on cognitive impairment, unlike the 
other imaging metrics which were not associated with cognitive impairment. One possible 
interpretation might be that WMLs reflect established structural tissue damage, whereas 
alterations in AAT and CBF reflect functional vascular changes. 
CBF differences between the IPD group and CN are in keeping with other imaging 
studies13,14,40,41.  For example, quantitative studies using PET have previously shown PD to be 
characterised by both hypoperfusion and hypometabolism in widespread cortical regions, 
particularly in frontal and parietal cortical regions, with occipital cortices probably more 
affected than the temporal cortex, and possibly also in some subcortical structures.15 The 
PIGD group had a more predominantly posterior pattern of hypoperfusion and indeed basal 
ganglia hyperperfusion than the more temporo-parieto-frontal hypoperfusion of the TD 
group (which did not show areas of hyperperfusion). To the authors’ knowledge the IPD 
phenotype differences revealed in this study have not been previously investigated. The 
noticeable pattern of hypoperfusion of the PIGD group, in the occipital cortex, 
encompassing the primary visual cortex, believed to be involved in gait and the more frontal 
TD regions felt to be involved in tremor42 may reflect differences in pathophysiology 
between IPD phenotypes and warrants further investigation. The region of hyperperfusion 
in the globus pallidus in patients is in keeping with previous findings of elevated glucose 
metabolism in this region.43  However, it may also be related to L-DOPA medication which 
has been shown to increase CBF in this region,44,45 particularly as the hyperperfusion is 
greatest in the PIGD group of whom a greater proportion were on L-DOPA medication (table 
1).  
Some would argue that perfusion changes are simply secondary to neuronal loss, if that 
were the case then one would expect a similar anatomical distribution of GM loss 
demonstrated by VBM to that of the reduction in perfusion, yet they are clearly distinct, 
with GM loss restricted to the temporal lobes.   Interestingly studies in AD at the preclinical 
stages and even in relatives of those with AD have revealed early perfusion changes43,44: this 
may suggest that some changes in perfusion in neurodegenerative states occur before 
neuronal loss. This raises an interesting hypothesis to be tested in IPD – that perfusion 
changes are a forerunner to, rather than a sequel of, neuronal loss. One possible mechanism 
is the impact of perfusion alterations on the regulation of brain metabolism,  as there is a 
close relationship between neurovascular and metabolic changes. For example, decreased 
mitochondrial electron transport chain activity has been implicated in PD pathogenesis, and 
there is some evidence to support the occurrence of parallel declines in the rate of cerebral 
oxygen consumption (CMRO2), glucose utilisation (CMRglc) and CBF in spatially contiguous 
cortical regions in early PD.48 There is a need for prodromal studies (for example, in specific 
individuals with genetic predisposition) and longitudinal studies temporally mapping 
vascular and neuronal changes. 
 Although we have investigated potential differences between PIGD and TD, in the present 
study PIGD patients had greater disease severity and higher LEDD score. When account was 
taken of this in the analysis, voxel-wise phenotypic differences in AAT did not persist. This 
may be in keeping with other recent observations using ASL MRI in patients with PD and PD 
dementia (PDD), which found widespread cortical hypoperfusion and further reductions in 
frontal lobe and cerebellum perfusion in PD and PDD respectively with dopaminergic 
medication.49 The observed patterns of hypoperfusion in this study were thought to 
potentially relate to cognitive dysfunction and disease severity. 
 
Aside from imaging, other studies reveal evidence of neurovascular changes in PD, 
supporting our findings. For example, CSF biomarkers of angiogenesis have been found to 
be increased in PD, and to be associated with gait difficulties, increased BBB permeability, 
WMLs, and cerebral microbleeds, indicating that abnormal angiogenesis may be relevant to 
PD pathogenesis and contribute to dopa-resistant symptoms.50 Other lines of evidence 
include pathological study of human PD cases showing endothelial degeneration and 
preservation of basement membrane leading to an increase of string vessel formation in PD. 
String vessels have no function in circulation, and this suggests a possible role for cerebral 
hypoperfusion in the neuronal degeneration characteristic of PD.51 
The main limitations to this study are that certain variables could not be controlled for 
including LEDD, disease duration and disease severity and these were found to differ 
between the disease phenotypes. To evaluate their potential impact they were included as 
nuisance co-variates in the  voxel-wise AAT and CBF comparisons. This resulted in removal 
of phenotypic imaging differences, suggesting that these imaging differences are driven in 
part by these factors.   
 
Conclusion 
This study has confirmed and added to our previous findings; namely, there is diffuse 
prolongation of AAT and reduced CBF in IPD patients by comparison with normal control 
subjects, and prolonged global AAT in IPD patients by comparison with controls subjects 
with CVD, despite significantly fewer vascular risk factors. TD patients showed lower WML 
volume by comparison with PIGD patients. These imaging data thus show altered NVS in 
IPD, with some evidence for IPD phenotype specific differences. Further studies are needed, 
likely longitudinal, to further investigate possible differences in the neurovascular 
contribution to the pathophysiology of particular IPD phenotypes, and to establish whether 
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Table 1. Demographics, clinical characteristics and whole brain perfusion measures. LEDD 
(levodopa equivalent daily dose); UPDRS 111 (unified Parkinson’s disease rating scale motor 
score). 
Table 2. Regions of CBF differences between groups at p<0.001, cluster size 50 voxels. 
Table 3. Regions of AAT differences between groups at p<0.001, cluster size 50 voxels. 
Table 4. WML rating scales and volumes (p value Pearson’s Chi squared for rating scales and 
Mann Whitney for WML volume). PVH, periventricular hyperintensity; DWMH, deep white 
matter hyperintensity.  
 
Figure legends 
Figure 1. Mean and standard error of whole brain CBF (a) and AAT (b). *p < 0.05, **p < 
0.005 
Figure 2. T-statistic maps showing regions of significantly higher (red) and lower (blue) CBF 
between pairwise group comparisons as indicated, thresholded at p < 0.001 uncorrected, 
minimum cluster size 50 voxels 
Figure 3. Prolonged AAT in IPD compared to controls. T statistic maps showing regions of 
significantly longer (red) and shorter (blue) AAT between pairwise group comparisons as 
indicated, thresholded at p < 0.001 uncorrected, minimum cluster size 50 voxels 
Figure 4. T-statistic maps showing regions of significantly greater (red) and less (blue) grey 
matter volume between pairwise group comparisons as indicated, thresholded at p < 0.001 
uncorrected, minimum cluster size 50 voxels 








All IPD  
(n=51) 
p   
(IPD vs. CN) 
p   






(PIGD vs. TD) 
Gender (F:M) 18:16 4:14 12:39 n/a n/a 5:19 7:15 n/a 






69.0 (7.7);  
[52-85] 






factors: mean (SD) 
1.4 (1.1) 3.1 (1.1) 1.7 (1.5) 0.4 0.0001 1.6 (1.4) 1.8 (1.6) 0.7 
Disease duration: 
mean (SD) 
n/a 1.1 (0.7) 7.2 (4.4) n/a n/a 9.1 (4.5) 5.1 (3.5) 0.07 
Hoehn & Yahr 
score: mean (SD) 
n/a n/a 2.6 (1.0) n/a n/a 3.2 (0.8) 1.8 (0.7) <0.0001 
UPDRS 111 Score: 
mean (SD) 
n/a n/a 30.2 (11.8) n/a n/a 29.9 (21.1) 26.3 
(10.8) 
0.05 
PIGD score: mean 
(SD) 
n/a n/a 6.8 (4.8) n/a n/a 9.2 (4.6) 1.8 (1.5) n/a 
Tremor score: mean 
(SD) 
n/a n/a 6.2 (5.2) n/a n/a 2.8 (3.0) 9.2 (4.6) n/a 
LEDD score (mg): 
mean (SD) 
n/a n/a 586.4 
(336.7) 
n/a n/a 785.9 (310.1) 370.0 (247.8) <0.0001 
MoCA score  
mean (SD) 
28.0 (2.3) 25.4 (3.3) 25.4 (3.8) 0.0004 1.0 23.8 (3.8) 27.3 (2.7) 0.0008 
Whole brain CBF 
(ml/min/100ml) ± SE 
46.7±8.8 43.4±7.0 47.5±11.5 1.0 0.06 49.6±13.4 46.7±8.9 0.7 
Whole brain AAT 
(ms) ± SE 
1376±157 1464±134 1525±168 <0.0001 0.04 1507±129 1527±209 0.7 













IPD < CN R middle frontal gyrus 176 0.3 4.6 <0.0001 44    54    12 






-18    -96    2 
2    -94    4 
-8    -98    -4 
L mid temporal gyrus extending to inferior gyrus and 
occipital region 






-66    -58    4 
-66    -54    -4 
-60    -66    2 
R mid temporal extending to mid occipital gyrus 96 0.5 4.2 <0.0001 50    -66    24 
R post central gyrus 61 0.6 4.0 <0.0001 32    -36    42 






-6    -64    58 
0    -68    48 
-2    -82    40 
L frontal superior medial region 57 0.7 3.9 0.0001 -4    66    12 






-30    -72    44 
-54    -66    30 
-46    -64    42 
IPD > CN R lateral globus pallidus 85 0.5 3.9 0.0001 20    -2    4 






22    -98    0 
-8    -100    0 
-40    -90    18 
L mid temporal to occipital gyrus 102 0.5 4.5 <0.0001 -64    -62    6 
L inferior occipital region 74 0.6 3.9 0.0001 -52    -74    -8 




-50    12    -6 
-48    16    -14 




50    -76    -2 
54    -68    -4 
R mid occipital region 60 0.7 3.7 0.0002 50    -68    26 
PIGD > CN Lentiform nucleus, lateral globus pallidus, putamen and 
limbic  lobe 






20    -12    -12 
20    -6         0 
30    -18    14 
TD <  CN 
 






52    -72    24 
40    -78    34 
38    -84    26 






46    54    6 
44    52    22 
36    62    14 
Transverse temporal area 76 0.6 4.6 <0.0001 70    -26    -6 



















L angular region extending to inferior temporal lobule and 
middle temporal gyrus 






-52    -64    40 
-46    -72    26 
-42    -78    38 




60    -52    0 




-64    -60    2 
-66    -52    -2 
L inferior parietal lobule 111 0.5 3.7 0.0001 
 
-58    -38    50 
 
R subgyral/post central gyrus 75 0.6 3.9 0.0001 26    -42    42 
Table 3. Regions of AAT differences between groups at p<0.001, cluster size 50 voxels. 










IPD > CN Large region L cerebrum most temporal lobe extending to the 
insula, parietal and frontal lobes including basal ganglia 






16    -74   6 
-26   -64   4 
-34    18    8 
R cerebrum extending to most temporal lobe, insula, parietal 
and frontal lobes inc BG 






36   -12    12 
50   -32    12 
40   -24   -2 




10    44    8 
-2    44    6 
R middle and inferior frontal lobe 213 0.6 3.9 <0.0001 10    40    42 
 
L amygdala 52 0.9 3.7 0.0002 -12   -16   -4 
PIGD > CN L superior to middle temporal gyrus 234 0.5 4.6 <0.0001 -26   -62    2 
L precuneus 190 0.6 4.0 <0.0001 -22   -74    18 






18     6     4 
26    -6    0 
32   -12   -2 
R sup. Temporal gyrus 222 0.5 3.9 0.0001 62   -32    12 
L angular gyrus 59 0.9 3.9 0.0002 -38   -56   26 
Sup. & L subgyral 
Temporal lobe 




-36   -40   0 
-38   -46   16 
L supramarginal  51 0.9 3.7 0.0002 -50   -46   28 
R calcarine 65 0.9 3.7 0.0002 14   -76    6 




-62   -34    10 
-54   -44    8 
R calcarine 88 0.9 3.7 0.0003 6   -68    18 
TD vs CN L post. Central gyrus extending to  frontal lobe, L insula and 
superior temporal gyrus, includes L caudate 






-52   -18    16 
-16    14    12 
-34   -4    14 






42   -8    12 
58   -4    10 
32    6     10 






0    -50    12 
16   -86    2 
16   -74    2 




-62   -30    -8 
-64   -38    -14 
L lingual 67 0.9 3.8 0.0002 -6   -80    2 




-18   -64    26 
-12   -76    18 




12    38   36 
10    46    32 
TD > PIGD R calcarine extending to cuneus 91 0.8 4.1 <0.0001 16   -86    2 
L frontal extending to caudate and limbic region 99 0.8 4.1 <0.0001 -14    16   -10 
L inferior frontal gyrus 53 0.9 4.1 <0.0001 -62    18    6 
L mid occipital and calcarine region 68 0.9 4.0 0.0001 -8   -112   -4 
R fronto- superior orbital region extending to R middle frontal 
gyrus 
74 0.9 3.9 0.0002 20    26   -24 
R middle occipital gyrus extending to calcarine region 52 0.9 3.8 0.0002 26   -102    0 













Table 4. WML rating scales and volumes (p value Pearson’s Chi squared for rating scales and Mann Whitney for WML volume). PVH, 
periventricular hyperintensity; DWMH, deep white matter hyperintensity. 
 
 CN (n=34) CP (n=18) All IPD (n=51) p value  
(IPD Vs. CN) 
p value  
(IPD Vs. CP) 
PIGD (n=24) TD (n=21) p value  
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Grey Matter Volume Group Differences 
L                       R 


















PIGD vs TD 
